334 filings
Page 13 of 17
8-K
a3uh6ww v446dx
3 Dec 19
INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study
4:06pm
8-K
20ur0d
29 Nov 19
INmune Bio Inc. to Discuss Potential New Alzheimer’s Disease Treatments in CTAD Pre-Conference Webinar
4:13pm
8-K
lv1mvxzwpko1q
20 Nov 19
INmune Bio, Inc. Strengthens Board of Directors with Appointment of Veteran Finance Executive Marcia Allen
4:30pm
8-K
klg3 45fv
12 Nov 19
INmune Bio, Inc. Reports Third Quarter 2019 Financial Results and Provides Shareholder Update
4:47pm
8-K
i7geyli4frnkown7 pir
21 Oct 19
INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience’s Annual Meeting
6:11am
8-K
a2u 15g27
8 Oct 19
INmune Bio Inc. to Present at Advances in Immuno-Oncology USA Congress and at World Immunotherapy Congress in October
4:30pm
8-K
v24bfql0o1yzt 1dt
30 Sep 19
Accomplishments at Nasdaq’s MarketSite and Announces Presentation at World Immunotherapy Congress
12:00am
8-K
vt9hgu
23 Sep 19
Regulation FD Disclosure
4:59pm
8-K
z41ja92evu1x09tp1
18 Sep 19
Regulation FD Disclosure
4:30pm
8-K
e4o6wfztmxcec9n
12 Sep 19
Submission of Matters to a Vote of Security Holders
4:31pm
8-K
t6yu91xvooo12 iyz
12 Sep 19
Inmune Bio Inc. Announces Uspto Allowance of Key Patent Covering Its DN-TNFΑ Platform Technology for Treating Cancer
4:30pm
8-K
jv2arbesd1iaosetb0
9 Sep 19
Regulation FD Disclosure
4:31pm
8-K
rn5zs
4 Sep 19
INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH
4:30pm
8-K
1y6sw18s3adn9ywqn
27 Aug 19
Regulation FD Disclosure
5:00pm
8-K
ba82inkxf4686
15 Aug 19
Regulation FD Disclosure
12:00am
8-K
bbl8 qpmzhut9l
13 Aug 19
INmune Bio Reports Second Quarter 2019 Financial Results and Provides Shareholder Update
4:36pm
DEF 14A
0npmaa39 9sjzq7mi
9 Aug 19
Definitive proxy
4:58pm
8-K
1zkv xvo4fmla4
9 Aug 19
INmune Bio Appoints Biotechnology Executive Edgardo Baracchini as New Board Member
4:38pm